Investing.com - Avalo Therapeutics (NASDAQ: AVTX) reported first quarter EPS of $-4.430, $3.66 worse than the analyst estimate of $-0.773. Revenue for the quarter came in at $5.2M versus the consensus estimate of $4.26M.
Avalo Therapeutics's stock price closed at $1.740. It is down -65.480% in the last 3 months and down -78.150% in the last 12 months.
Avalo Therapeutics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Avalo Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Avalo Therapeutics's Financial Health score is "weak performance".
Check out Avalo Therapeutics's recent earnings performance, and Avalo Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar